PT - JOURNAL ARTICLE AU - dos Santos Soares, Tainá AU - Bello, Graziele Lima AU - dos Santos Petry, Ianca Moraes AU - Nicola, Maria Rita Castilho AU - Vitoria da Silva, Larissa AU - Barcellos, Regina Bones AU - Silvestri, Joana Morez AU - Rossetti, Maria Lucia AU - Costa, Alexandre Dias Tavares TI - Laboratory validation of a simplified DNA extraction protocol followed by a portable qPCR detection of <em>M. tuberculosis</em> DNA suitable for point of care settings AID - 10.1101/2024.04.05.24305384 DP - 2024 Jan 01 TA - medRxiv PG - 2024.04.05.24305384 4099 - http://medrxiv.org/content/early/2024/04/07/2024.04.05.24305384.short 4100 - http://medrxiv.org/content/early/2024/04/07/2024.04.05.24305384.full AB - Tuberculosis, caused by Mycobacterium tuberculosis, is a treatable and curable disease, and yet remains one of the leading causes of death worldwide. Diagnosis is essential to reducing the number of cases and starting treatment, but costly tests and equipments that require complex infrastructure hamper their widespread use as a tool to contain the disease in vulnerable populations as well countries lacking resources. Therefore, it becomes necessary to develop new technological approaches to molecular methods as well as screening tests that can be rapidly conducted among people presenting to a health facility to differentiate those who should have further diagnostic evaluation for TB from those who should undergo further investigation for non-TB diagnoses. The present study aimed to evaluate two experimental DNA extraction methods from clinical samples (FTA card versus sonication) followed by analysis in a portable qPCR instrument (the Q3-plus). The FTA card-based protocol showed 100% sensitivity and specificity, while the sonication protocol showed 80% sensitivity and 89% specificity when compared to the traditional gold standard culture. The portable protocol, comprised by the FTA card method and the portable instrument Q3-Plus, showed sensitivity and specificity of 92% and 61%, respectively, when compared to culture, and 75% and 81%, respectively, when compared to the standard TB case classification. The ROC curve showed an AUC of 0.78 (p&lt;0.001) for the portable protocol and 0.93 (p&lt;0.001) for the GeneXpert MTB/RIF. The limit of detection (LOD) for Mycobacterium tuberculosis (H37Rv strain) detection in spiked samples obtained using the portable protocol (FTA card and Q3-Plus) was 19.3 CFU/mL. As an added benefit, using the FTA card facilitates sample handling, transport, and storage. It is concluded that the use of the FTA card protocol and the Q3-Plus yields similar sensitivity and specificity as the gold standard diagnostic tests and case classification. We suggest that the platform is suitable to use as a point of care tool, assisting in the screening of tuberculosis in hard-to-reach or resource-limited areas.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grant CNPq 445954/2020-5 from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, https://www.gov.br/cnpq/pt-br) to ADTC and INCT-TB FAPERGS 17/1265 from CNPq and Fundacao de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS, https://fapergs.rs.gov.br/inicial) to MLRR. TSS is a fellowship holder at CAPES (Fundacao Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, https://www.gov.br/capes/pt-br). ADTC is a CNPq Productivity Fellow (level 2).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by the Ethics Committee of Universidade Luterana do Brasil (0697116.7.0000.5349 to GLB) and by the Ethics Committee of Fundacao Oswaldo Cruz (CAAE 4423120.0.1001.5248 to ADTC)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.